Gilead Sciences (GILD) Stock Forecast, Price Target & Predictions
GILD Stock Forecast
Gilead Sciences stock forecast is as follows: an average price target of $80.00 (represents a -3.39% downside from GILD’s last price of $82.81) and a rating consensus of 'Buy', based on 20 wall street analysts offering a 1-year stock forecast.
GILD Price Target
The average price target for Gilead Sciences (GILD) is $80.00 based on 1-year price targets from 20 Wall Street analysts in the past 3 months, with a price target range of $95.00 to $54.00. This represents a potential -3.39% downside from GILD's last price of $82.81.
GILD Analyst Ratings
According to 20 Wall Street analysts, Gilead Sciences's rating consensus is 'Buy'. The analyst rating breakdown for GILD stock is 0 'Strong Buy' (0.00%), 11 'Buy' (55.00%), 8 'Hold' (40.00%), 1 'Sell' (5.00%), and 0 'Strong Sell' (0.00%).
Gilead Sciences Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Sep 12, 2024 | Salveen Richter | Goldman Sachs | $71.00 | $82.85 | -14.30% | -14.26% |
| Sep 12, 2024 | Terence Flynn | Morgan Stanley | $79.00 | $82.63 | -4.39% | -4.60% |
| Sep 11, 2024 | Joseph Catanzaro | Piper Sandler | $95.00 | $79.93 | 18.85% | 14.72% |
| Aug 14, 2024 | Asthika Goonewardene | Truist Financial | $83.00 | $74.14 | 11.95% | 0.23% |
| Aug 09, 2024 | Evan David Seigerman | BMO Capital | $85.00 | $75.59 | 12.45% | 2.64% |
| Aug 09, 2024 | Brian Abrahams | RBC Capital | $72.00 | $75.59 | -4.75% | -13.05% |
| Jul 08, 2024 | Steven Seedhouse | Raymond James | $93.00 | $67.76 | 37.25% | 12.31% |
| Jun 24, 2024 | Michael Yee | Jefferies | $85.00 | $71.24 | 19.31% | 2.64% |
| Jun 20, 2024 | Brian Skorney | Robert W. Baird | $80.00 | $69.21 | 15.59% | -3.39% |
| Jun 17, 2024 | Salim Syed | Mizuho Securities | $90.00 | $64.52 | 39.50% | 8.68% |
The latest Gilead Sciences stock forecast, released on Sep 12, 2024 by Salveen Richter from Goldman Sachs, set a price target of $71.00, which represents a -14.30% decrease from the stock price at the time of the forecast ($82.85), and a -14.26% decrease from GILD last price ($82.81).
Gilead Sciences Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 3 | 10 | 15 |
| Avg Price Target | $81.67 | $83.30 | $81.07 |
| Last Closing Price | $82.81 | $82.81 | $82.81 |
| Upside/Downside | -1.38% | 0.59% | -2.10% |
In the current month, the average price target of Gilead Sciences stock is $81.67, according to 3 Wall Street analysts offering twelve months forecast. The average price target represents a -1.38% decrease as opposed to Gilead Sciences's last price of $82.81. This month's average price target is down -1.96% compared to last quarter, and up 0.74% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 12, 2024 | Goldman Sachs | Neutral | Neutral | Hold |
| Sep 12, 2024 | Morgan Stanley | Reduce | Reduce | Hold |
| Sep 12, 2024 | BMO Capital | Outperform | Outperform | Hold |
| Sep 11, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Sep 04, 2024 | Raymond James | Underperform | Underperform | Hold |
| Aug 15, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Aug 15, 2024 | RBC Capital | Sector Perform | Sector Perform | Hold |
| Aug 09, 2024 | Goldman Sachs | Neutral | Neutral | Hold |
| Aug 09, 2024 | BMO Capital | Outperform | Outperform | Hold |
| Aug 09, 2024 | RBC Capital | Outperform | Outperform | Hold |
Gilead Sciences's last stock rating was published by Goldman Sachs on Sep 12, 2024. The company gave GILD a "Neutral" rating, the same as its previous rate.
Gilead Sciences Financial Forecast
Gilead Sciences Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | $7.12B | $7.05B | $6.60B | $6.35B | $7.39B | $7.04B | $6.26B | $6.59B | $7.24B | $7.42B | $6.22B | $6.42B | $7.42B | $6.58B | $5.14B | $5.55B | $5.88B | $5.60B | $5.68B | $5.28B | $5.09B | $6.50B |
| Avg Forecast | $7.24B | $7.06B | $6.88B | $6.56B | $7.15B | $6.97B | $6.70B | $6.36B | $7.10B | $6.81B | $6.45B | $6.33B | $6.64B | $6.13B | $5.86B | $6.29B | $6.61B | $6.29B | $6.08B | $6.74B | $7.08B | $6.29B | $5.29B | $5.45B | $5.72B | $5.61B | $5.53B | $5.30B | $5.74B | $6.65B |
| High Forecast | $7.68B | $7.49B | $7.30B | $6.96B | $7.58B | $7.38B | $7.11B | $6.74B | $7.27B | $7.02B | $6.84B | $6.71B | $7.04B | $6.50B | $6.21B | $6.66B | $7.01B | $6.67B | $6.44B | $7.14B | $7.50B | $6.66B | $5.60B | $5.78B | $6.06B | $5.94B | $5.86B | $5.61B | $6.89B | $7.98B |
| Low Forecast | $7.05B | $6.88B | $6.70B | $6.39B | $6.96B | $6.78B | $6.53B | $6.19B | $6.89B | $6.63B | $6.29B | $6.17B | $6.46B | $5.97B | $5.71B | $6.12B | $6.44B | $6.12B | $5.92B | $6.56B | $6.89B | $6.12B | $5.15B | $5.31B | $5.56B | $5.46B | $5.38B | $5.16B | $4.59B | $5.32B |
| # Analysts | 6 | 12 | 6 | 6 | 7 | 14 | 7 | 9 | 10 | 21 | 10 | 10 | 13 | 9 | 9 | 16 | 10 | 10 | 19 | 13 | 10 | 15 | 9 | 9 | 8 | 8 | 12 | 16 | 19 | 15 |
| Surprise % | - | - | - | - | - | - | - | - | 1.00% | 1.04% | 1.02% | 1.00% | 1.11% | 1.15% | 1.07% | 1.05% | 1.10% | 1.18% | 1.02% | 0.95% | 1.05% | 1.05% | 0.97% | 1.02% | 1.03% | 1.00% | 1.03% | 1.00% | 0.89% | 0.98% |
Gilead Sciences's average Quarter revenue forecast for Mar 24 based on 9 analysts is $6.36B, with a low forecast of $6.19B, and a high forecast of $6.74B. GILD's average Quarter revenue forecast represents a -10.65% decrease compared to the company's last Quarter revenue of $7.12B (Dec 23).
Gilead Sciences EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 6 | 12 | 6 | 6 | 7 | 14 | 7 | 9 | 10 | 21 | 10 | 10 | 13 | 9 | 9 | 16 | 10 | 10 | 19 | 13 | 10 | 15 | 9 | 9 | 8 | 8 | 12 | 16 | 19 | 15 |
| EBITDA | - | - | - | - | - | - | - | - | $1.61B | $2.62B | $1.67B | $2.01B | $2.42B | $3.11B | $2.08B | $86.00M | $1.53B | $4.23B | $2.69B | $3.06B | $2.57B | $2.59B | $2.14B | $2.59B | $2.49B | $-904.00M | $3.01B | $2.96B | $2.68B | $4.17B |
| Avg Forecast | $2.58B | $2.51B | $2.45B | $2.33B | $2.54B | $2.48B | $2.38B | $619.71M | $2.52B | $2.42B | $2.29B | $563.37M | $2.36B | $2.48B | $2.08B | $512.15M | $2.35B | $2.24B | $2.16B | $3.02B | $2.52B | $2.23B | $1.88B | $2.44B | $2.03B | $1.99B | $1.97B | $2.69B | $2.98B | $4.27B |
| High Forecast | $2.73B | $2.66B | $2.59B | $2.47B | $2.70B | $2.62B | $2.53B | $743.65M | $2.59B | $2.49B | $2.43B | $676.04M | $2.50B | $2.97B | $2.21B | $614.59M | $2.49B | $2.37B | $2.29B | $3.62B | $2.67B | $2.37B | $1.99B | $2.93B | $2.15B | $2.11B | $2.08B | $3.23B | $3.58B | $5.12B |
| Low Forecast | $2.51B | $2.45B | $2.38B | $2.27B | $2.47B | $2.41B | $2.32B | $495.77M | $2.45B | $2.36B | $2.23B | $450.70M | $2.30B | $1.98B | $2.03B | $409.72M | $2.29B | $2.18B | $2.10B | $2.41B | $2.45B | $2.18B | $1.83B | $1.95B | $1.98B | $1.94B | $1.91B | $2.15B | $2.39B | $3.41B |
| Surprise % | - | - | - | - | - | - | - | - | 0.64% | 1.08% | 0.73% | 3.57% | 1.02% | 1.25% | 1.00% | 0.17% | 0.65% | 1.89% | 1.24% | 1.01% | 1.02% | 1.16% | 1.14% | 1.06% | 1.23% | -0.45% | 1.53% | 1.10% | 0.90% | 0.98% |
9 analysts predict GILD's average Quarter EBITDA for Mar 24 to be $619.71M, with a high of $743.65M and a low of $495.77M. This is -61.56% lower than Gilead Sciences's previous annual EBITDA (Dec 23) of $1.61B.
Gilead Sciences Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 6 | 12 | 6 | 6 | 7 | 14 | 7 | 9 | 10 | 21 | 10 | 10 | 13 | 9 | 9 | 16 | 10 | 10 | 19 | 13 | 10 | 15 | 9 | 9 | 8 | 8 | 12 | 16 | 19 | 15 |
| Net Income | - | - | - | - | - | - | - | - | $1.43B | $2.18B | $2.14B | $1.01B | $1.64B | $1.79B | $1.14B | $12.00M | $376.00M | $2.59B | $1.52B | $1.73B | $1.55B | $360.00M | $-3.35B | $1.55B | $2.70B | $-1.17B | $1.88B | $1.98B | $1.54B | $2.70B |
| Avg Forecast | $2.34B | $2.26B | $2.17B | $2.06B | $1.93B | $1.96B | $2.01B | $19.05M | $2.20B | $2.40B | $2.05B | $17.32M | $1.90B | $1.52B | $1.90B | $15.75M | $1.99B | $2.20B | $2.18B | $1.74B | $2.55B | $2.44B | $1.81B | $1.45B | $2.09B | $2.18B | $2.15B | $1.79B | $1.71B | $2.76B |
| High Forecast | $2.53B | $2.43B | $2.35B | $2.22B | $2.08B | $2.30B | $2.17B | $22.86M | $2.55B | $2.61B | $2.22B | $20.78M | $2.05B | $1.83B | $2.04B | $18.90M | $2.15B | $2.37B | $2.35B | $2.08B | $2.75B | $2.63B | $1.95B | $1.74B | $2.25B | $2.35B | $2.32B | $2.15B | $2.06B | $3.31B |
| Low Forecast | $2.26B | $2.18B | $2.10B | $1.99B | $1.87B | $1.71B | $1.94B | $15.24M | $1.99B | $2.15B | $1.98B | $13.86M | $1.83B | $1.22B | $1.83B | $12.60M | $1.92B | $2.12B | $2.10B | $1.39B | $2.46B | $2.36B | $1.74B | $1.16B | $2.02B | $2.10B | $2.08B | $1.43B | $1.37B | $2.21B |
| Surprise % | - | - | - | - | - | - | - | - | 0.65% | 0.91% | 1.04% | 58.31% | 0.86% | 1.17% | 0.60% | 0.76% | 0.19% | 1.18% | 0.70% | 1.00% | 0.61% | 0.15% | -1.85% | 1.07% | 1.29% | -0.54% | 0.87% | 1.10% | 0.90% | 0.98% |
Gilead Sciences's average Quarter net income forecast for Mar 24 is $19.05M, with a range of $15.24M to $22.86M. GILD's average Quarter net income forecast represents a -98.67% decrease compared to the company's last Quarter net income of $1.43B (Dec 23).
Gilead Sciences SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 6 | 12 | 6 | 6 | 7 | 14 | 7 | 9 | 10 | 21 | 10 | 10 | 13 | 9 | 9 | 16 | 10 | 10 | 19 | 13 | 10 | 15 | 9 | 9 | 8 | 8 | 12 | 16 | 19 | 15 |
| SG&A | - | - | - | - | - | - | - | - | $1.61B | $1.31B | $1.85B | $1.32B | $2.02B | $1.21B | $1.36B | $1.08B | $1.65B | $1.19B | $1.35B | $1.05B | $1.73B | $1.11B | $1.24B | $1.08B | $1.20B | $1.05B | $1.09B | $1.03B | $997.00M | $850.00M |
| Avg Forecast | $1.49B | $1.45B | $1.41B | $1.35B | $1.47B | $1.43B | $1.38B | $1.09B | $1.46B | $1.40B | $1.33B | $987.27M | $1.36B | $699.38M | $1.20B | $897.51M | $1.36B | $1.29B | $1.25B | $1.06B | $1.45B | $1.29B | $1.09B | $1.01B | $1.17B | $1.15B | $1.14B | $934.04M | $1.11B | $868.64M |
| High Forecast | $1.58B | $1.54B | $1.50B | $1.43B | $1.56B | $1.52B | $1.46B | $1.30B | $1.49B | $1.44B | $1.41B | $1.18B | $1.45B | $839.26M | $1.28B | $1.08B | $1.44B | $1.37B | $1.32B | $1.27B | $1.54B | $1.37B | $1.15B | $1.21B | $1.24B | $1.22B | $1.20B | $1.12B | $1.33B | $1.04B |
| Low Forecast | $1.45B | $1.41B | $1.38B | $1.31B | $1.43B | $1.39B | $1.34B | $868.79M | $1.42B | $1.36B | $1.29B | $789.81M | $1.33B | $559.50M | $1.17B | $718.01M | $1.32B | $1.26B | $1.22B | $848.04M | $1.42B | $1.26B | $1.06B | $806.32M | $1.14B | $1.12B | $1.11B | $747.23M | $888.34M | $694.91M |
| Surprise % | - | - | - | - | - | - | - | - | 1.10% | 0.94% | 1.39% | 1.34% | 1.48% | 1.73% | 1.13% | 1.21% | 1.21% | 0.92% | 1.08% | 1.00% | 1.19% | 0.86% | 1.14% | 1.07% | 1.03% | 0.91% | 0.96% | 1.10% | 0.90% | 0.98% |
Gilead Sciences's average Quarter SG&A projection for Mar 24 is $1.09B, based on 9 Wall Street analysts, with a range of $868.79M to $1.30B. The forecast indicates a -32.46% fall compared to GILD last annual SG&A of $1.61B (Dec 23).
Gilead Sciences EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 6 | 12 | 6 | 6 | 7 | 14 | 7 | 9 | 10 | 21 | 10 | 10 | 13 | 9 | 9 | 16 | 10 | 10 | 19 | 13 | 10 | 15 | 9 | 9 | 8 | 8 | 12 | 16 | 19 | 15 |
| EPS | - | - | - | - | - | - | - | - | $1.15 | $1.75 | $1.71 | $0.81 | $1.31 | $1.43 | $0.91 | $0.01 | $0.30 | $2.06 | $1.21 | $1.38 | $1.24 | $0.29 | $-2.67 | $1.23 | $2.13 | $-0.92 | $1.48 | $1.55 | $1.18 | $2.07 |
| Avg Forecast | $1.87 | $1.80 | $1.74 | $1.64 | $1.54 | $1.56 | $1.61 | $-1.49 | $1.76 | $1.92 | $1.64 | $1.52 | $1.52 | $1.43 | $1.52 | $1.80 | $1.59 | $1.76 | $1.74 | $2.08 | $2.04 | $1.95 | $1.44 | $1.57 | $1.67 | $1.74 | $1.72 | $1.61 | $1.86 | $2.33 |
| High Forecast | $2.02 | $1.95 | $1.87 | $1.77 | $1.67 | $1.84 | $1.73 | $-1.44 | $2.04 | $2.09 | $1.77 | $1.64 | $1.64 | $1.54 | $1.63 | $1.94 | $1.72 | $1.89 | $1.87 | $2.24 | $2.20 | $2.10 | $1.56 | $1.70 | $1.80 | $1.87 | $1.85 | $1.74 | $2.23 | $2.80 |
| Low Forecast | $1.81 | $1.74 | $1.68 | $1.59 | $1.49 | $1.37 | $1.55 | $-1.61 | $1.59 | $1.72 | $1.59 | $1.47 | $1.47 | $1.38 | $1.46 | $1.74 | $1.54 | $1.70 | $1.68 | $2.01 | $1.97 | $1.88 | $1.39 | $1.52 | $1.61 | $1.68 | $1.66 | $1.55 | $1.49 | $1.86 |
| Surprise % | - | - | - | - | - | - | - | - | 0.65% | 0.91% | 1.04% | 0.53% | 0.86% | 1.00% | 0.60% | 0.01% | 0.19% | 1.17% | 0.70% | 0.66% | 0.61% | 0.15% | -1.85% | 0.78% | 1.28% | -0.53% | 0.86% | 0.96% | 0.63% | 0.89% |
According to 9 Wall Street analysts, Gilead Sciences's projected average Quarter EPS for Mar 24 is $-1.49, with a low estimate of $-1.61 and a high estimate of $-1.44. This represents a -229.84% decrease compared to GILD previous annual EPS of $1.15 (Dec 23).
Gilead Sciences Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| PFE | Pfizer | $29.27 | $46.29 | 58.15% | Hold |
| BMY | Bristol-Myers Squibb Company | $49.13 | $65.43 | 33.18% | Hold |
| MRK | Merck | $115.86 | $127.74 | 10.25% | Buy |
| AZN | AstraZeneca | $78.27 | $84.33 | 7.74% | Buy |
| JNJ | Johnson & Johnson | $165.52 | $176.29 | 6.51% | Buy |
| GILD | Gilead Sciences | $82.81 | $80.00 | -3.39% | Buy |
| AMGN | Amgen | $332.45 | $286.95 | -13.69% | Buy |
| ABBV | AbbVie | $194.21 | $167.54 | -13.73% | Buy |
| LLY | Eli Lilly and Company | $923.71 | $753.65 | -18.41% | Buy |
GILD Forecast FAQ
Is Gilead Sciences a good buy?
Yes, according to 20 Wall Street analysts, Gilead Sciences (GILD) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 11 'Buy' recommendations, accounting for 55.00% of GILD's total ratings.
What is GILD's price target?
Gilead Sciences (GILD) average price target is $80 with a range of $54 to $95, implying a -3.39% from its last price of $82.81. The data is based on 20 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Gilead Sciences stock go up soon?
According to Wall Street analysts' prediction for GILD stock, the company can go down by -3.39% (from the last price of $82.81 to the average price target of $80), up by 14.72% based on the highest stock price target, and down by -34.79% based on the lowest stock price target.
Can Gilead Sciences stock reach $120?
GILD's average twelve months analyst stock price target of $80 does not support the claim that Gilead Sciences can reach $120 in the near future.
What is Gilead Sciences's current price target trend?
3 Wall Street analysts forecast a $81.67 price target for Gilead Sciences (GILD) this month, down -1.38% from its last price of $82.81. Compared to the last 3 and 12 months, the average price target increased by 0.59% and decreased by -2.10%, respectively.
What are Gilead Sciences's analysts' financial forecasts?
Gilead Sciences's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $27.17B (high $28.81B, low $26.46B), average EBITDA is $8.02B (high $8.59B, low $7.7B), average net income is $5.92B (high $6.57B, low $5.53B), average SG&A $5.36B (high $5.84B, low $5.03B), and average EPS is $3.22 (high $3.79, low $2.8). GILD's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $27.75B (high $29.43B, low $27.02B), average EBITDA is $9.87B (high $10.46B, low $9.61B), average net income is $8.83B (high $9.53B, low $8.53B), average SG&A $5.7B (high $6.05B, low $5.55B), and average EPS is $7.06 (high $7.61, low $6.82).
Did the GILD's actual financial results beat the analysts' financial forecasts?
Based on Gilead Sciences's last annual report (Dec 2023), the company's revenue was $27.12B, beating the average analysts forecast of $26.7B by 1.56%. Apple's EBITDA was $7.6B, missing the average prediction of $7.8B by -2.55%. The company's net income was $5.66B, missing the average estimation of $6.67B by -15.06%. Apple's SG&A was $6.09B, beating the average forecast of $5.17B by 17.75%. Lastly, the company's EPS was $4.54, missing the average prediction of $6.84 by -33.63%. In terms of the last quarterly report (Dec 2023), Gilead Sciences's revenue was $7.12B, beating the average analysts' forecast of $7.1B by 0.20%. The company's EBITDA was $1.61B, missing the average prediction of $2.52B by -36.15%. Gilead Sciences's net income was $1.43B, missing the average estimation of $2.2B by -35.04%. The company's SG&A was $1.61B, beating the average forecast of $1.46B by 10.21%. Lastly, the company's EPS was $1.15, missing the average prediction of $1.76 by -34.60%